Golimumab

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Ulcerative Colitis

Conditions

Ulcerative Colitis

Trial Timeline

May 9, 2014 → May 25, 2016

NCT ID

NCT02092285

About Golimumab

Golimumab is a approved stage product being developed by Merck for Ulcerative Colitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02092285. Target conditions include Ulcerative Colitis.

What happened to similar drugs?

14 of 20 similar drugs in Ulcerative Colitis were approved

Approved (14) Terminated (5) Active (6)

✅Azathioprine + PlaceboCelltrionApproved

✅Filgotinib MaleateEisaiApproved

✅Oral Upadacitinib + Intravenous Methylprednisolone + Oral Upadacitinib Placebo + Oral prednisolone Taper + Oral Prednisone - Hospital Dose SteroidsAbbVieApproved

✅AdalimumabAbbVieApproved

✅Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg + Golimumab treatment optimization.MerckApproved

✅GolimumabMerckApproved

✅Prefilled Syringe delivery of Golimumab + Smartject Device delivery of GolimumabMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03270501	Phase 3	Completed	Nov 8, 2017	Dec 14, 2023	Axial Spondyloarthritis
NCT03124121	Approved	Completed	Sep 5, 2017	Sep 30, 2019	Ulcerative Colitis
NCT02841176	Pre-clinical	Terminated	Jul 1, 2016	Sep 19, 2017	Psoriatic Arthritis
NCT02318667	Approved	Completed	Feb 27, 2015	Sep 5, 2017	Colitis, Ulcerative
NCT02092285	Approved	Completed	May 9, 2014	May 25, 2016	Ulcerative Colitis
NCT01668004	Approved	Completed	Sep 3, 2012	Apr 30, 2015	Ankylosing Spondylitis

Competing Products

20 competing products in Ulcerative Colitis

See all competitors

Product	Company	Stage	Hype Score
Mirikizumab SC + Mirikizumab IV + Placebo SC	Eli Lilly	Phase 3	40
Mirikizumab	Eli Lilly	Phase 2	35
Azathioprine + Placebo	Celltrion	Approved	35
CT-P13 SC (Infliximab)	Celltrion	Phase 3	40
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	44
Tacrolimus	Astellas Pharma	Phase 3	40
tacrolimus + Placebo	Astellas Pharma	Phase 3	40
Filgotinib Maleate	Eisai	Approved	50
AJM300 + Placebo	Eisai	Phase 3	40
GSK3050002 + Placebo	Eisai	Phase 1	29
adalimumab + placebo	Eisai	Phase 3	40
E6007 + Placebo	Eisai	Phase 2	35
KHK4083 + Placebo	Kyowa Kirin	Phase 2	35
KHK4083 + Placebo	Kyowa Kirin	Phase 1	29
Arm1 + Arm 2	Zydus Lifesciences	Phase 2	35
Mirikizumab + Mirikizumab	Eli Lilly	Phase 3	44
Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SC	Eli Lilly	Phase 3	32
LY3471851 + Placebo	Eli Lilly	Phase 2	27
Mirikizumab + Placebo	Eli Lilly	Phase 2	35
LY4268989 + Placebo	Eli Lilly	Phase 2	42